ImpediMed Reports 15% Revenue Growth and Expands SOZO Platform Reach

Revenue Growth and Reimbursement Expansion

ImpediMed Limited (ASX:IPD) has posted a 15% increase in revenue for the financial year ended 30 June 2026, reaching $14.6 million, driven primarily by new SOZO system sales and recurring revenue growth in North America. In constant currency terms, revenue was up 20%. The company’s reimbursement coverage for breast cancer-related lymphoedema now extends to 95% of the US population, up from 82% the previous year, underscoring the growing acceptance of its SOZO Digital Health Platform in clinical practice.

The installed base of SOZO systems grew 9% globally to 1,236 units, with 642 units in the US, reflecting steady adoption in key markets. Patient testing volume also rose, with 324,000 tests conducted in FY26 alone, a 13% year-on-year increase, and a total of over 1.5 million tests since launch.

Platform Diversification into Heart Health and Weight Management

Building on its foundation in breast cancer-related lymphoedema, ImpediMed has expanded the SOZO platform into two adjacent markets: heart health and medical weight management. SOZO Pro, the latest generation system, is the only FDA-cleared bioimpedance spectroscopy device for assessing fluid status in heart failure patients, including those with cardiac implantable devices. Medicare now covers approximately 75% of heart failure patients for SOZO, opening a $600 million estimated US outpatient monitoring market.

In medical weight management, the rise of GLP-1 therapies has created demand for body composition monitoring beyond simple weight metrics. SOZO Pro’s integrated weight measurement combined with BodyComp™ Analysis offers clinicians detailed insights into fat, muscle, and hydration status, supporting personalised care. Clinical guidelines from leading societies increasingly endorse bioimpedance for this purpose, indicating a growing market opportunity.

Leadership Changes and Financial Discipline

April 2026 saw a leadership transition with Erik Anderson appointed CEO, bringing two decades of US commercial healthcare experience, including senior roles at Hologic. Anderson has emphasised commercial execution, sales discipline, and financial rigor as the company scales its platform across multiple markets.

In June 2026, ImpediMed completed a $15.3 million capital raise, deploying $5 million of proceeds to partially repay its debt facility and implementing $5 million in annualised operating cost reductions. These actions, combined with revenue growth, position the company on a clearer path toward operating cash flow breakeven.

Financial Performance and Operating Loss

Despite revenue growth, ImpediMed reported a net loss of $24.9 million for FY26, slightly wider than the $23.2 million loss in FY25. The increased loss primarily reflects higher finance expenses related to its credit facility. Operating expenses remained steady at $35.2 million, with reductions in salaries and share-based payments partially offsetting other costs.

Cash and cash equivalents stood at $15.3 million at year-end, down from $22.2 million, with net cash used in operating activities rising to $17.9 million. The company’s balance sheet reflects ongoing investments in commercial expansion and product development.

Governance, ESG, and Market Position

ImpediMed continues to strengthen its governance framework, with a Board comprising independent directors and a focus on accountability. The company maintains HITRUST certification for its SOZO platform, underscoring its commitment to data security and patient privacy.

Environmental and social responsibility initiatives include sustainable manufacturing practices and community engagement, particularly in cancer survivorship forums. Diversity remains a priority, with women representing over half of company-wide employees and 50% of the executive team.

Strategic Outlook and Market Opportunities

ImpediMed’s strategy focuses on deepening penetration in lymphoedema and survivorship care, expanding utilisation within existing customers, and scaling heart health and weight management segments with disciplined commercial execution. The company’s integrated SOZO platform, offering multiple FDA-cleared applications from a single non-invasive scan, positions it well to capture growing demand across these converging healthcare markets.

However, the path to profitability remains contingent on sustaining revenue growth, managing costs, and expanding reimbursement coverage. The company’s recent capital raise and cost reductions provide runway, but execution risk persists amid competitive and regulatory landscapes.